ResMed (NYSE:RMD) posts better-than-expected sales in Q3 CY2026
ResMed reported Q3 CY2026 revenue of $1.41 billion, exceeding estimates by 1.7% and growing 5.9% year-on-year. Adjusted EPS was $2.91, an 8.9% beat. Operating and free cash flow margins declined slightly from the prior year.
How this was made
The 30-second read
Why it matters
A clear earnings beat on revenue and adjusted EPS is likely to support near-term sentiment, but the year-over-year declines in operating margin and free-cash-flow margin suggest investors may discount the quality of the beat.
Market read
Traders can reassess near-term valuation and expectations based on the beat, while monitoring whether margin and cash conversion weakness persists.
What to watch
Constant-currency revenue rose 7% while operating and FCF margins fell, so traders may want to focus on what drove the margin compression (pricing, mix, expenses) rather than the headline beat.
Background
The piece summarizes ResMed’s Q3 CY2026 results versus S&P analysts’ consensus, including revenue, adjusted EPS, and margin metrics.
Ticker impact
ResMed reported Q3 CY2026 revenue of $1.41B vs $1.39B consensus and adjusted EPS $2.91 vs $2.67, both beats.
Likely modest upward pressure as the market prices in the earnings beat, offset by concerns from lower operating and free-cash-flow margins.
The article provides explicit beat figures for revenue and adjusted EPS, while also stating operating margin and free-cash-flow margin fell year over year, which typically limits multiple expansion.
Market effects
Signals demand and pricing resilience in medical devices/respiratory care, but weaker cash conversion may raise scrutiny on cost discipline across the group.
Primarily US-listed single-name earnings impact; limited direct regional spillover implied by the provided data.
Constant-currency revenue growth indicates international performance, but no region-specific breakdown is provided.
Counterpoint
The margin and free-cash-flow margin declines could indicate cost inflation or mix headwinds, meaning the EPS beat may not translate into stronger cash generation going forward.
Key entities
- companyResMed
NYSE-listed medical device company reporting Q3 CY2026 revenue, adjusted EPS, and margin metrics versus consensus.
